Navigation Links
MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters
Date:8/23/2007

New Facility Allows MedImmune to Meet Increasing Demands for Clinical Trial

Materials from Company's Expanding and Advancing Pipeline

GAITHERSBURG, Md., Aug. 23 /PRNewswire-FirstCall/ -- MedImmune today unveiled a new, state-of-the-art pilot lab facility located on the same Gaithersburg site as its headquarters. With its cutting-edge equipment and process automation systems, the facility will support MedImmune's expanding clinical product pipeline by providing additional capacity and flexibility.

At a ribbon-cutting event for the pilot lab held today at MedImmune, David M. Mott, president and chief executive officer, stated: "Completing this new facility is an important milestone, signaling our continued growth and success as a world-class biopharmaceuticals company. The opening of this facility, alongside the expansion work underway on our new biologics facility in Frederick, Maryland, reaffirms our leadership role within the state's biotechnology industry and demonstrates our ongoing commitment to the region."

The new pilot lab's 5,000 liters of bioreactor capacity will result in a four-fold increase in production capabilities. With the expanded facility, MedImmune will be able to produce clinical trial materials at a greater scale and in greater quantities, aiding in the testing of potential new products.

"This substantial increase in MedImmune's clinical production infrastructure supports our robust pipeline of product candidates," said Gail Folena-Wasserman, Ph.D., senior vice president, development. "The pilot lab facility is intended to meet our current and future needs, not just through its increased capacity but also through design flexibility, which efficiently allows us to produce multiple clinical products in the same space. We can drive efficiency and meet rigorous quality standards by incorporating the latest technology, including an advanced process control system."

In December 2006, the City of Gaithersburg approved the new pilot lab facility for occupancy. The facility will become the primary site for production of MedImmune's therapeutic proteins, replacing the existing Gaithersburg Manufacturing Development Facility (GMDF) where those clinical trial materials are currently produced. Material production is expected to begin in 2008, following the final stages of equipment validation. MedImmune plans to upgrade GMDF in the near future to provide added support for its development needs.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With approximately 3,000 employees worldwide and headquarters in Maryland, MedImmune is wholly owned by AstraZeneca plc (NYSE: AZN). For more information, visit MedImmune's website at http://www.medimmune.com.


'/>"/>
SOURCE MedImmune
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The Why Files celebrates decade of science exploration
2. Young Professionals of Milwaukee Celebrates Its Third Birthday, Looks To The Future
3. Internet Scout celebrates 10 years on web, eyes new project launch
4. Farm Aid celebrates 20-year journey, heads back to Illinois roots
5. UW Office of Corporate Relations Celebrates Early Accomplishments
6. Its All Fun And Games in Madison - Raven Software Celebrates 15 Anniversary
7. Merge files financial reports by market opening
8. RFID pilot project aims to improve blood banks
9. Pilot fund brings capital to Eau Claire area innovations
10. National $100m pilot program to begin mapping cancer genome
11. Milwaukee health provider network pilots software plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... HOUSTON , Jan. 19, 2017 /PRNewswire/ ... the formation of its Medical/Clinical Advisory Board.  This ... veterans who enhance the range and depth of ... of its novel prenatal diagnostic tests.  These experts ... strategic guidance for the company,s product development and ...
(Date:1/19/2017)... and GAITHERSBURG, Md. ... MKT: PIP) and Altimmune, Inc., a privately-held immunotherapeutics ... of a definitive agreement for the merger of ... current investors include Novartis Venture Fund, HealthCap, Truffle ... be a fully-integrated and diversified immunotherapeutics company with ...
(Date:1/19/2017)... Staten Island, NY (PRWEB) , ... January 19, 2017 , ... ... expand at an exponential rate. The tremendous growth is accounted to two main ... to the table and the expanding network of vendors supplying FireflySci products all around ...
(Date:1/19/2017)... BD (Becton, Dickinson and Company) (NYSE: BDX ), a ... live webcast of its Annual Meeting of Shareholders on Tuesday, January ... can be accessed from the BD corporate website at http://www.bd.com/investors/ ... ... BD is a global medical technology company that is ...
Breaking Biology Technology:
(Date:1/3/2017)... , Jan. 3, 2017 Onitor, provider of ... of Onitor Track, an innovative biometric data-driven program designed ... this month at the 2017 Consumer Electronics Show (CES) ... In the U.S., the World Health Organization (WHO), ... two-thirds of adults who are overweight or obese. WHO ...
(Date:12/19/2016)... BARCELONA , España y TORONTO , 19 ... fusión con Northern Biologics Inc. que permitirá el desarrollo acelerado de ... ensayos clínicos en varios tipos de tumor en 2017, con múltiples ... ... de su clase con objetivo en el factor inhibidor de leucemia ...
(Date:12/15/2016)... 15, 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... company, announced today that on December 13, 2016, it ... The Nasdaq Stock Market LLC which acknowledged that, as ... WaferGen,s common stock had been at $1.00 or greater ... compliance with Listing Rule 5550(a)(2) of the Nasdaq Stock ...
Breaking Biology News(10 mins):